-
1.发明公开
公开(公告)号：EP3572409A1
公开(公告)日：2019-11-27
申请号：EP18742199.5
申请日：2018-01-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： HUANG, Ticong , XIAO, Huifeng , ZHAO, Rui , LIU, fei , WEI, Wei , XU, Hongjiang , WANG, Xiaojin , WU, Jingli
IPC分类号： C07D401/14 , A61K31/5377 , A61P35/00
摘要： The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl) -N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.
-
2.发明公开
公开(公告)号：EP3533796A1
公开(公告)日：2019-09-04
申请号：EP17863410.1
申请日：2017-10-27
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , HU, Yuandong , WU, Wei , DAI, Liguang , DUAN, Xiaowei , YANG, Yanqing , SUN, Yinghui , HAN, Yongxin , PENG, Yong , KONG, Fansheng , LUO, Hong , YANG, Ling , XU, Hongjiang , GUO, Meng , ZHONG, Zhaobai , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377
摘要： Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
-
公开(公告)号：EP3505516A1
公开(公告)日：2019-07-03
申请号：EP17842961.9
申请日：2017-08-24
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： TANG, Song , ZHU, Yizhong , LIU, Fei , ZHOU, Jie , CHEN, Zhilin , XU, Hongjiang , TIAN, Xin
IPC分类号： C07D401/12 , C07C57/145 , C07C51/41 , A61K31/517 , A61P35/00
摘要： Disclosed are a crystal of a maleate of a compound of formula (I), a preparation method for the crystal, a crystallization composition of same, a pharmaceutical composition of same, and uses thereof in preventing and treating a tumor.
-
公开(公告)号：EP3330258A1
公开(公告)日：2018-06-06
申请号：EP16829878.4
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHAO, Na , WANG, Shulong , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , HAN, Yongxin , ZHANG, Xiquan , XU, Hongjiang
IPC分类号： C07D251/18 , C07D251/26 , A61K31/53 , A61P35/00
CPC分类号： A61K31/53 , C07D251/18 , C07D251/26
摘要： Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.
-
公开(公告)号：EP3272746B1
公开(公告)日：2019-12-25
申请号：EP16767717.8
申请日：2016-03-18
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHANG, Xiquan , TANG, Song , FENG, Weiwei , TIAN, Xin , CHEN, Zhilin , GU, Hongmei , XU, Hongjiang , LIU, Fei
IPC分类号： C07D403/12 , C07D401/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00 , A61K31/4427 , A61K45/06 , C07D239/94 , C07D211/40
-
公开(公告)号：EP3323817A1
公开(公告)日：2018-05-23
申请号：EP16823908.5
申请日：2016-07-15
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Yan , ZHAO, Na , SHANG, Xianxing , HU, Yuandong , PENG, Yong , ZHANG, Hui , LIU, Bo , LUO, Hong , HAN, Yongxin , YANG, Ling , XU, Hongjiang
IPC分类号： C07D403/04 , C07D413/04 , A61K31/506 , A61P35/00 , A61P35/02
CPC分类号： C07D403/04 , A61K31/506 , A61K31/5377 , A61P35/00 , C07D413/04
摘要： The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases.
-
7.发明公开
公开(公告)号：EP3828183A1
公开(公告)日：2021-06-02
申请号：EP19842279.2
申请日：2019-07-25
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Shouyao Holdings (Beijing) Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： LI, Jijun , ZHU, Yan , WANG, Yeliu , SHANG, Xianxing , WANG, Huting , HE, Weinan , YAN, Qin , SUN, Yinghui , ZHANG, Kai , LU, Chang , XU, Hongjiang , TIAN, Xin , YANG, Ling
IPC分类号： C07D471/04 , C07D487/04 , A61K31/437 , A61K31/407 , A61K31/18 , A61P35/00 , A61P35/02
摘要： The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.
-
公开(公告)号：EP3272746A1
公开(公告)日：2018-01-24
申请号：EP16767717.8
申请日：2016-03-18
申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHANG, Xiquan , TANG, Song , FENG, Weiwei , TIAN, Xin , CHEN, Zhilin , GU, Hongmei , XU, Hongjiang , LIU, Fei
IPC分类号： C07D403/12 , C07D401/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00
摘要： The present application relates to maleates of a compound of Formula I, methods for preparing the same, pharmaceutical compositions thereof and uses thereof in the treatment of tumors, such as non-small cell lung cancer, breast cancer, and other malignant tumors.
摘要翻译： 本申请涉及式I化合物的马来酸盐，其制备方法，其药物组合物及其在治疗肿瘤如非小细胞肺癌，乳腺癌和其他恶性肿瘤中的用途。
-
9.发明公开
公开(公告)号：EP3434676A1
公开(公告)日：2019-01-30
申请号：EP17769492.4
申请日：2017-03-27
申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： WANG, Shulong , CHEN, Kuncheng , LIU, Xijie , HU, Yuandong , LIU, Bo , PENG, Yong , LUO, Hong , HAN, Yongxin , WANG, Shanchun , LIU, Mei , XU, Hongjiang
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02
摘要： The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
-
公开(公告)号：EP4424676A1
公开(公告)日：2024-09-04
申请号：EP22886123.3
申请日：2022-10-28
发明人： LIU, Fei , XU, Hongjiang , PENG, Yan , SHI, Wei , ZHOU, Jiawei , GU, Jiajia
IPC分类号： C07D249/08 , C07D403/14 , C07D401/14 , A61K31/4196 , A61P35/00
CPC分类号： C07D401/14 , C07D249/08 , C07D403/14 , A61P35/00 , A61K31/4196
摘要： Provided are a pyridyl-containing compound represented by formula I and a preparation method therefor, and the use thereof in the preparation for a drug for treating tumors.
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.021 秒)
